(Reuters) - Trial data for AstraZeneca AZN.L and University of Oxford's possible coronavirus vaccine could be given to regulators this year, a scientist leading the trials said on Tuesday.
Drugmakers are racing to combat the pandemic, which has killed about 810,000 people and infected roughly 24 million.
There are no approved vaccines for COVID-19, but AstraZeneca’s vaccine is widely seen as one of the leading candidates, with reports that the United States is aiming for a fastrack approval before the November presidential election.
The company has been granted protection from future product liability claims related to the vaccine by most of the countries with which it has so far struck supply agreements, a senior executive told Reuters.
Below are the main details of the vaccine and its supply and production deals.
Reporting by Pushkala Aripaka in Bengaluru; Additional reporting by Tanishaa Nadkar; Editing by Jan Harvey and Mark Potter
Our Standards: The Thomson Reuters Trust Principles.